European Journal of Cardiovascular Medicine

Background: Mycobacterium wis an immunomodulatorthat evokes antigen-specific cell-mediated immunity and its use has been evaluated in patients with sepsis, where it resulted in improved outcome.  Methods: We collected data in ten adult patientswith suspected gram-negative sepsis admitted inthe intensive care unit. Injection Mw 0.3 ml was administered intradermal per day for three consecutive days alongwith continuation of standard care. Results: We observed clinical improvement and a significant decrease in TLC and SOFA Score on day 7 after Mw administration. Also, Mw was not associated with any local or systemic adverse effects. Conclusion: The use of Mw was safe and effective in patients with sepsis, though larger randomized trials are required to establish its role.